Fig. 2From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation typesSurvival curves in lung adenocarcinoma patients harbouring EGFR mutations who received tyrosine kinase inhibitors. a Comparison of progression-free survival according to mutation type. b Comparison of overall survival according to mutation type. c Comparison of progression-free survival according to treatment regimen. d Comparison of overall survival according to treatment regimenBack to article page